SAN FRANCISCO (AP) — A record 621 people died of drug overdoses in San Francisco so far this year, a staggering number that far outpaces the 173 deaths from COVID-19 the city has seen thus far.
The crisis fueled by the powerful painkiller fentanyl could have been far worse if it wasn’t for the nearly 3,000 times Narcan was used from January to the beginning of November to save someone from the brink of death, the San Francisco Chronicle reported Saturday.READ MORE: San Francisco Safeway Adds Barriers To Deter Rampant Shoplifting
The data reflects the number of times people report using Narcan to the Drug Overdose Prevention and Education Project, a city-funded program that coordinates San Francisco’s response to overdose, or return to refill their supply. Officials at the DOPE Project said that since the numbers are self-reported, they are probably a major undercount.
Last year, 441 people died of drug overdoses—a 70% increase from 2018—and 2,610 potential overdoses were prevented by Narcan, a medication commonly sprayed up the nose to reverse an opioid overdose, according to data from the city Medical Examiner’s office and the DOPE Project.READ MORE: SF Supervisor Preston Proposes 10-Day Warning Period For Renters Facing Eviction
The crisis is deepening because fentanyl, which can be 50 to 100 times more potent than morphine, flooded the city’s drug supply, the newspaper said. Moreover, the coronavirus pandemic has disrupted city services like housing and treatment, and left many people who rely on others to help save them if they overdose to use alone.
While nearly 40% of the deaths occurred in the Tenderloin and South of Market neighborhoods near downtown, city data showed the epidemic has touched every part of the city. Many people overdosed in low-income apartment buildings and in city-funded hotel rooms for the homeless. Others died on sidewalks, in alleyways and parks around the city.MORE NEWS: Redwood City Retail Theft Suspect Arrested; Stolen Home Depot Merchandise Recovered
Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.